Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.
US Markets continued to witness volatility on Monday as President Donald Trump's 'Liberation Day' fast approaches, bringing a volley of tariffs across products, industries, allies, and adversaries. Leading analysts and experts have since urged the President to reconsider his trade policy stance.
The stock market faced a challenging day as risk sentiment remained under pressure on Wall Street. The S&P 500 experienced a volatile session, hitting its lowest point in over six months before recovering some losses. The S&P ended the day 0.5% higher at 5,611.85. Despite this, the index is on track for its worst month since September 2022, with a 7% decline in March.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 12.5% in the morning session after Peter Marks, the head of the FDA's Center for Biologics Evaluation and Research (CBER), resigned on Friday, 28 March 2025. Marks noted his departure was related to "misinformation and lies" around immunization and raised concerns about the Trump administration's ability to "swiftly approve critical vaccines."
Risk sentiment remains under pressure at the start of the week on Wall Street, with tech-heavy indexes sliding while commodities advance, as traders fear a new wave of price pressures following the upcoming tariffs announcement.
Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19."We are pleased to receive regulatory approval for mRESVIA in Australia following the TGA's decision," said Stéphane Bancel, Chief Executive Officer of Moderna. "This approval underscores our commitment to protecting older adults from RSV-related respiratory diseases. We look forward to supplying mRESVIA from our Melbourne facility to older Australians vulnerable to RSV in the future."
Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Wednesday. Stay informed about the latest market trends.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst performers in the therapeutics industry.
